Long-term prognosis of polypoidal choroidal vasculopathy with a 5-year remission after an initial combination therapy.
Combination therapy
Polypoidal choroidal vasculopathy
Remission
Visual prognosis
Journal
Photodiagnosis and photodynamic therapy
ISSN: 1873-1597
Titre abrégé: Photodiagnosis Photodyn Ther
Pays: Netherlands
ID NLM: 101226123
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
received:
27
05
2021
revised:
15
07
2021
accepted:
19
07
2021
pubmed:
25
7
2021
medline:
16
9
2021
entrez:
24
7
2021
Statut:
ppublish
Résumé
To investigate the visual prognosis of patients with polypoidal choroidal vasculopathy (PCV) with a 5-year remission after an initial combination therapy involving photodynamic therapy (PDT) and intravitreal ranibizumab (IVR) or aflibercept injection (IVA). Medical records of 69 consecutive patients with PCV treated with PDT with IVR/IVA were retrospectively reviewed, and 17 eyes were identified with a 5-year remission after the initial combination therapy. The eyes that did not require additional treatment during the 1 During the 7-year follow-up, the mean logarithm of the minimal angle resolution best-corrected visual acuity (logMAR BCVA) significantly improved from 0.39±0.27 to 0.17±0.38 (p=2.9 × 10 The combination therapy showed a favourable outcome for PCV over a 7-year follow-up, especially in the eyes without recurrence during the 1
Identifiants
pubmed: 34303031
pii: S1572-1000(21)00277-5
doi: 10.1016/j.pdpdt.2021.102453
pii:
doi:
Substances chimiques
Angiogenesis Inhibitors
0
Photosensitizing Agents
0
Ranibizumab
ZL1R02VT79
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
102453Informations de copyright
Copyright © 2021. Published by Elsevier B.V.